Coherus BioSciences (FRA:8C5) COGS-to-Revenue : 0.45 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences COGS-to-Revenue?

Coherus BioSciences's Cost of Goods Sold for the three months ended in Mar. 2024 was €31.8 Mil. Its Revenue for the three months ended in Mar. 2024 was €70.9 Mil.

Coherus BioSciences's COGS to Revenue for the three months ended in Mar. 2024 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Coherus BioSciences's Gross Margin % for the three months ended in Mar. 2024 was 55.12%.

Coherus BioSciences COGS-to-Revenue Historical Data

The historical data trend for Coherus BioSciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences COGS-to-Revenue Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.05

0.08

0.18

0.33

0.62

Coherus BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.52	0.42	0.44	0.92	0.45

Coherus BioSciences COGS-to-Revenue Calculation

Coherus BioSciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	145.796	/	235.893
	=	0.62

Coherus BioSciences's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	31.819	/	70.898
	=	0.45

Coherus BioSciences (FRA:8C5) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Coherus BioSciences's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	31.819 / 70.898
	=	55.12 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Coherus BioSciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (FRA:8C5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines